Genelabs Technologies, Inc.

GOLETA, Calif.--(BUSINESS WIRE)-- Serimmune, a leader in understanding the antibody repertoire’s role in human disease, announced today the appointment of Gary Schroth, PhD, Vice President and Distinguished Scientist at Illumina, to its Scientific Advisory Board (SAB). As an industry veteran in genomics and next-generation sequencing (NGS), Dr. Schroth brings more than 25 years of scientific and leadership experience to this role. At Illumina, he currently oversees the Core Applications Group in Product Development and previously held several positions in research and development at Solexa (now part of Illumina), Applied Biosystems (now part of Thermo Fisher Scientific), Genelabs Technologies and Gen-Probe. Dr. Schroth uses NGS tools in his research to study gene structure, expression and regulation as it applies to cancer, functional genomics, immunology, microbiology and infectious disease. He earned both his PhD and Bachelor of Science in biochemistry from the University of California at Davis. Throughout his career, he has published more than 100 peer reviewed research papers and holds 17 US patents. “We continue to expand the scientific and technological expertise of our SAB with the addition of Dr. Schroth and remain focused on identifying and exploiting the relationships between antibody repertoire and human disease,” said Chief Executive Officer Malek Faham. About Serimmune Serimmune is a leader in understanding antibody repertoire and is focused on identifying and exploiting the universe of relationships between antibodies and antigens. The company’s Serum Epitope Repertoire Analysis (SERA) technology platform applies bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Serimmune’s human immunity map is a growing database that can be interrogated to uncover disease information for the development of multiplex diagnostics, vaccines and therapeutics. The company was founded in 2014 and is backed by investors such as Illumina Ventures, LabCorp, and Merck. For more information visit serimmune.com or follow us on Facebook, Twitter and LinkedIn.

July 18, 2022 11:00 UTC Dr. Liu is a clinical leader who brings expertise in the discovery, development, and regulatory approval of oncology therapies worldwide Ms. Wentworth has over two decades of industry experience in domestic and international regulatory and quality affairs NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer. Dr. Liu will lead Nuvation Bio’s clinical development team and collaborate with the executive committee to provide strategic direction for the Company’s research and drug development programs. Ms. Wentworth will oversee regulatory and quality affairs across the Company’s pipeline. “I am honored to join Nuvation Bio and oversee the clinical development of innovative therapies for the most difficult-to-treat cancers,” said Dr. Liu. “I look forward to working with this experienced and dedicated team to address the unmet needs of cancer patients.” “Nuvation Bio’s mission to bring meaningful cancer treatments to patients who have nearly exhausted all options deeply resonates with me,” said Ms. Wentworth. “The Company is taking on this bold challenge with tenacity and urgency, and I am proud to contribute to this important work.” Dr. Liu brings over 20 years of experience leading the discovery and development of oncology therapies, including New Drug Application (NDA) submissions for multiple oncology assets in the U.S., Europe, and China. Most recently, Dr. Liu served as the Chief Medical Officer at a biotechnology company based in Shanghai, China. There, he built and led their clinical research and development organization, including global clinical research, global clinical operations, pharmacovigilance, biostatistics, programming and data management, clinical pharmacology, and drug supply. Ms. Wentworth has over 25 years of experience in domestic and international regulatory and quality affairs. Her background spans early and late development across multiple therapeutic areas, including oncology, osteoarthritis, pain management, autoimmune disorders, and rare diseases. She also has a broad scope of product knowledge, ranging from injectable small molecules to complex autologous platforms. Ms. Wentworth most recently served as Chief Regulatory Officer at Flexion Therapeutics, which was acquired by Pacira Biosciences in 2021, setting and delivering on regulatory and quality strategies across their product portfolio. Notably, Ms. Wentworth was instrumental in leading the company’s first NDA successfully into commercialization. “We are pleased for David and Kerry to join the Nuvation Bio team and believe their decades of focused experience at leading global biopharmaceutical companies will significantly contribute to the development of our various programs,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “We look forward to working with them as we aim to meaningfully improve the lives of cancer patients.” Earlier in his career, Dr. Liu held several roles of increasing strategic responsibility at Bristol Myers Squibb, where he became a leader in Oncology Global Clinical Research, including leading the Global Prostate Cancer Program, Pediatric Clinical Development, and Translational Research for ipilimumab, and development of nivolumab and ipilimumab for China. After Bristol Myers Squibb, Dr. Liu was the Global Lead Physician at Celgene for the revlimid plus rituximab submission program in indolent lymphoma. Dr. Liu earned a Ph.D. from the Massachusetts Institute of Technology, an M.S. from the University of Toledo, and an M.D. from Beijing Medical University (Peking University School of Medicine). Prior to joining Flexion, Ms. Wentworth served as Vice President, Clinical, Regulatory, and Quality at Agenus, Inc., where she led all global regulatory and clinical development efforts. Previously, Ms. Wentworth led the regulatory and quality function for Genelabs Technologies, Inc., and prior to that held positions of increasing responsibility within Regulatory Affairs at Genzyme. Ms. Wentworth holds a B.S. in pre-veterinary medicine from the University of New Hampshire. About Nuvation Bio Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit .

REDWOOD CITY, Calif., May 2 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that a presentation was made today at the 20th International Conference on Antiviral Research being held in Palm Springs, California, on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs. The oral presentation was given by Christopher D. Roberts, Ph.D., Director of Medicinal Chemistry at Genelabs, entitled "GL59728: A Potent Allosteric Inhibitor of the HCV NS5b RNA Dependent RNA Polymerase with Excellent Pharmacokinetic Properties." GL59728 is one of a number of non-nucleoside HCV polymerase inhibitors discovered by Genelabs. In the presentation, Dr. Roberts outlined the lead optimization of certain non-nucleoside HCV polymerase inhibitors through an iterative process involving testing for potency in directly inhibiting HCV NS5b polymerase, inhibiting the replication of an HCV sub-genomic replicon, and pharmacokinetic properties. The optimized lead that emerged from this chemistry approach, one of several taken by Genelabs, is known as GL59728. The IC50 of GL59728 for inhibition of the HCV NS5b polymerase is 16 nanomolar and the EC50 for inhibition of HCV replicon is 170 nanomolar. Further, GL59728 shows excellent oral bioavailability, exceeding 50% in all four species tested, including higher-order species, low clearance and a half-life consistent with once- or twice-daily dosing. The tissue distribution of GL59728 also appears favorable; since its concentration is enhanced several fold in liver, the site of HCV infection, relative to that obtained in plasma. Importantly, GL59728 was also tested in combination with other classes of HCV antiviral compounds, including a nucleoside chain terminator, a protease inhibitor and interferon alpha, and shown to be additive in activity with each. In June 2006 Genelabs entered into a license and research collaboration with Novartis covering Genelabs' non-nucleoside HCV polymerase inhibitors. "The data presented today clearly support the further investigation of non-nucleoside polymerase inhibitors for the future treatment of HCV infection," said Ronald C. Griffith, Ph.D., Genelabs' Chief Scientific Officer. "Furthermore, we believe future treatment of HCV is likely to involve combinations of antiviral drugs and these data suggest that combinations of this type of non-nucleoside agent with interferon or other likely therapeutic drugs, such as nucleoside chain terminators or protease inhibitors, may be feasible." About Genelabs Technologies Genelabs Technologies, Inc. is a biopharmaceutical company focused on the discovery and development of pharmaceutical products to improve human health. We have built drug discovery capabilities that can support various research and development projects. Genelabs is currently concentrating these capabilities on discovering novel compounds that selectively inhibit replication of the hepatitis C virus and advancing preclinical development of compounds from this hepatitis C virus drug discovery program, while also developing a late-stage product for lupus. We believe that these high-risk, potentially high reward programs focus our research and development expertise in areas where we have the opportunity to generate either first-in-class or best-in-class products that will address diseases for which current therapies are inadequate. For more information, please visit . NOTE: Genelabs(R) and the Genelabs logo are registered trademarks and Prestara(TM) is a trademark of Genelabs Technologies, Inc. NOTE ON FORWARD LOOKING STATEMENTS AND RISKS: This press release contains forward-looking statements including statements on the feasibility of non-nucleoside polymerase inhibitors for the future treatment of HCV infection and the prospects for GL59728. These forward-looking statements are based on Genelabs' current expectations and are subject to uncertainties and risks that could cause actual results to differ materially from the statements made. Uncertainties and risks include, without limitation, that further testing will not yield positive results or that alternative compounds which may be at an earlier stage may be given preference over GL59728 for future development. Please see the information appearing in the Genelabs' filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, under the captions "Risk Factors" and "Forward-Looking Statements" for more discussion regarding these uncertainties and risks and others associated with the company's research programs, early stage of development and other risks which may affect the company or cause actual results to differ from those included in the forward-looking statements. Genelabs does not undertake any obligation to update these forward-looking statements or risks to reflect events or circumstances after the date of this release. Contact: James A. D. Smith President and Chief Executive Officer Phone: 650-562-1424 Genelabs Technologies, Inc. CONTACT: James A. D. Smith, President and Chief Executive Officer ofGenelabs Technologies, Inc., +1-650-562-1424 Web site: